vatalanib has been researched along with Experimental Neoplasms in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allegrini, PR; Boulay, A; Brueggen, J; Lane, HA; Littlewood-Evans, A; Maira, SM; Martiny-Baron, G; McSheehy, PM; O'Reilly, T; Schnell, CR; Sini, P; Wood, JM | 1 |
| Brandt, R; Hynes, NE; Littlewood, A; O'Reilly, T; Schnell, C; Sini, P; Wood, J; Wyder, L | 1 |
| Bucana, CD; Carter, KB; Jasser, SA; Kim, S; Myers, JN; Wang, Z; Yazici, YD | 1 |
| Wood, JM | 1 |
| Baker, CH; Bucana, CD; Fidler, IJ; McCarty, MF | 1 |
5 other study(ies) available for vatalanib and Experimental Neoplasms
| Article | Year |
|---|---|
mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Topics: Angiogenesis Inhibitors; Animals; Cell Movement; Cell Proliferation; Everolimus; Female; Humans; Immunoenzyme Techniques; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms, Experimental; Neovascularization, Pathologic; Phthalazines; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Rats; Rats, Inbred BN; Rats, Inbred WF; Receptor, TIE-2; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Tissue Distribution; TOR Serine-Threonine Kinases; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2009 |
The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Coculture Techniques; Drug Synergism; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; ErbB Receptors; Fluorescent Antibody Technique; Gefitinib; Humans; Immunoblotting; In Situ Nick-End Labeling; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Phthalazines; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Pyridines; Quinazolines; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2005 |
Antivascular therapy of oral tongue squamous cell carcinoma with PTK787.
Topics: Animals; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Therapy, Combination; Follow-Up Studies; In Vitro Techniques; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Phthalazines; Prodrugs; Protein Kinase Inhibitors; Pyridines; Tongue Neoplasms; Treatment Outcome | 2005 |
Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Topics: Angiogenesis Inhibitors; Animals; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Endothelium, Vascular; Humans; Lymphokines; Mice; Mice, Nude; Neoplasms, Experimental; Neovascularization, Pathologic; Phthalazines; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |
Quantitative and qualitative in vivo angiogenesis assay.
Topics: Angiogenesis Inhibitors; Animals; Biological Assay; Female; Fluorescent Antibody Technique; Gelatin Sponge, Absorbable; Humans; In Vitro Techniques; Mice; Mice, Inbred C3H; Neoplasms, Experimental; Neovascularization, Physiologic; Phthalazines; Platelet Endothelial Cell Adhesion Molecule-1; Protein-Tyrosine Kinases; Pyridines | 2002 |